Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 6/20 | 0.88 |
| ▸ | OXTR | P30559 | 15/20 | 0.88 |
| ▸ | AVPR2 | P30518 | 5/20 | 0.88 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demoxytocin SCHEMBL38443 | 1.00 | AVPR1A (0.88) | AVPR1AOXTRAVPR2AVPR1B | |
| Demoxytocin SCHEMBL38442 | 1.00 | AVPR1A (0.88) | AVPR1AOXTRAVPR2AVPR1B | |
| Oxytocin SCHEMBL28086558 | 0.97 | OXTR (0.93) | AVPR1AOXTRAVPR2AVPR1B | |
| Oxytocin Trisulfide SCHEMBL30712243 | 0.97 | AVPR1A (0.86) | AVPR1AOXTRAVPR2AVPR1B | |
| SCHEMBL15511632 | 0.95 | AVPR1A (0.80) | AVPR1AOXTRAVPR2AVPR1B | |
| SCHEMBL22333521 | 0.95 | AVPR1A (0.79) | AVPR1AOXTRAVPR2AVPR1B | |
| SCHEMBL15511860 | 0.94 | OXTR (0.81) | AVPR1AOXTRAVPR2AVPR1B | |
| SCHEMBL15511596 | 0.94 | AVPR1A (1.00) | AVPR1AOXTRAVPR2AVPR1B | |
| Oxytocin SCHEMBL29048 | 0.94 | OXTR (1.00) | AVPR1AOXTRAVPR2AVPR1B | |
| Oxytocin SCHEMBL21527573 | 0.94 | OXTR (1.00) | AVPR1AOXTRAVPR2AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3242676-B1 | MAGNESIUM-CONTAINING OXYTOCIN FORMULATIONS AND METHODS OF USE | TONIX Pharmaceuticals Holding Corp (US) | 2023-10-04 | — | — | EP | claimed |
| WO-2022200568-A1 | TREATMENT OF DYSPHAGIA | OT4B (FR) | 2022-09-29 | — | — | WO | claimed |
| US-20260053883-A1 | OXYTOCIN COMPOSITIONS FOR TREATMENT OF VISUAL SNOW SYNDROME | MASKBEGONE LLC (US) | 2026-02-26 | — | — | US | disclosed |
| WO-2025245322-A1 | OXYTOCIN-BASED THERAPEUTICS TO IMPROVE COGNITIVE CONTROL IN INDIVIDUALS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | THE GENERAL HOSPITAL CORPORATION (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12466855-B2 | Labeled oxytocin and method of manufacture and use | TONIX PHARMA LIMITED (IE) | 2025-11-11 | — | — | US | disclosed |
| US-20250319153-A1 | MAGNESIUM-CONTAINING OXYTOCIN FORMULATIONS AND METHODS OF USE | TONIX PHARMA LTD (IE) | 2025-10-16 | — | — | US | disclosed |
| US-20250255930-A1 | METHODS OF TREATMENT OF TINNITUS USING DERIVATIVES OF OXYTOCIN | MASKBEGONE LLC (US) | 2025-08-14 | — | — | US | disclosed |
| CN-120091810-A | Methods and highly bioavailable permeable compounds for treating viral diseases | 基里尔·迪丹克 | 2025-06-03 | — | — | CN | disclosed |
| EP-4541348-A2 | MAGNESIUM-CONTAINING OXYTOCIN FORMULATIONS AND METHODS OF USE | Tonix Pharma Limited (IE) | 2025-04-23 | — | — | EP | disclosed |
| US-12156897-B2 | Magnesium-containing oxytocin formulations and methods of use | TONIX PHARMA LIMITED (IE) | 2024-12-03 | — | — | US | disclosed |
| EP-3442560-B1 | MAGNESIUM-CONTAINING OXYTOCIN FORMULATIONS AND METHODS OF USE | TONIX PHARMA LTD (IE) | 2024-11-20 | — | — | EP | disclosed |
| CN-109414476-B | Magnesium-containing oxytocin formulations and methods of use | 三叉神经股份公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115647329-A | Solution method for reducing invasive pores in aluminum alloy casting | 安徽博煊铸造有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-109963553-B | Oral delivery vehicle | 费尔廷制药公司 | 2022-11-22 | — | — | CN | disclosed |
| WO-2022200568-A1 | TREATMENT OF DYSPHAGIA | OT4B (FR) | 2022-09-29 | — | — | WO | disclosed |
| CN-109952092-B | Tablet comprising separate binder and erythritol | 费尔廷制药公司 | 2022-08-23 | — | — | CN | disclosed |
| US-11389473-B2 | Magnesium-containing oxytocin formulations and methods of use | TONIX PHARMACEUTICALS HOLDING CORP. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-4021410-A1 | OXYTOCIN COMPOSITIONS FOR TREATMENT OF TINNITUS | New York University (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11266711-B2 | Oxytocin compositions and methods of use | ELGAN PHARMA LTD (IL) | 2022-03-08 | — | — | US | disclosed |
| US-11241477-B2 | Oxytocin compositions for treatment of tinnitus | NEW YORK UNIVERSITY (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053883-A1 | OXYTOCIN COMPOSITIONS FOR TREATMENT OF VISUAL SNOW SYNDROME | OXTR, AVPR2, AVPR1B | AVPR1A 4/4885OXTR 1/4885AVPR2 2/4885 |
| US-12466855-B2 | Labeled oxytocin and method of manufacture and use | OXTR, AVPR1A, AVPR1B | AVPR1A 2/4885OXTR 1/4885AVPR2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.